ABOUT US

Building leadership in topical therapies for Immunology and Inflammation (I&I)

MC2 Therapeutics is a commercial stage pharmaceutical company committed to optimize the treatment experience and address unmet needs for patients with autoimmune and chronic inflammatory conditions through innovative best in class or first in class topical therapies tailored for fast and safe relief of symptoms in formulations that patients prefer to use in daily routines.

PAD™ Technology redefines topical therapies and allows oil-in-water formulations that go beyond technical limitations of conventional topical formulations. It is a powerful tool to release the full potential of active ingredients in formulations designed to maximize patient adherence. PAD™ Technology enables next generation topical therapies to address all the three essentials in a single product: 

Efficacy: PAD™ Technology enables optimization of key formulation parameters relevant to the delivery of active ingredients into the target tissue, thereby releasing the full potential effect.

Tolerability: PAD™ Technology enables formulations with multi-fold less emulsifiers/surfactants compared to conventional oil-in-water formulations, thereby setting the foundation of topical therapies with favorable safety and tolerability profiles.

Adherence: Real world efficacy is directly dependent on patient adherence to therapy. Patient adherence may be the largest barrier to treatment success.1 In order to incorporate adherence into the daily routine of using topical treatment options, they must be easy to apply and quickly absorb into the skin (non-staining) within a few minutes, so it is practical and pleasant to use.

Using PAD™ Technology as our cornerstone in our formulations, we remain committed to research root causes of poorly understood diseases and to develop innovative new therapies, including for indications where there are currently no approved treatments such as uremic pruritus, lichen sclerosus and Sjogren dry eye.

Read more about PAD™ based Wynzora® Cream drug for plaque psoriasis here.

Read more about our pipeline of  PAD™ based drug candidates here.

Read more about our PAD™ based biomee™ skin care line for dry, itchy and sensitive skin here.

References:

  1. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Alinia H, Moradi Tuchayi S, Smith JA, Richardson IM, Bahrami N, Jaros SC, Sandoval LF, Farhangian ME, Anderson KL, Huang KE, Feldman SR  Br J Dermatol. 2017;176(3):759. Epub 2016 Nov 29
COMPANY PRESENTATION

We are dedicated to respond beyond expectations by redefining topical therapies and patient treatment experience within immunology and inflammation.

Read all about our platform, pipeline and purpose in our corporate presentation.

© mc2 therapeutics 2020